The examples that support this are investigations of ACY-1215 in combination with anti-PD-L1 therapy in ovarian carcinoma [243], ACY-241 in combination with anti-PD-L1 antibodies in MM [208], Nex A in combination with anti-PD-1 antibodies in melanoma [141], etc. Based on similar and growing experimental data, a considerable number of clinical studies have been conducted in advanced solid tumors. Here, CD274 is linked to melanoma.